Mary Ann E. Moore Sells 8,108 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) Stock

Pediatrix Medical Group, Inc. (NYSE:MD) EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock traded down $0.46 during mid-day trading on Tuesday, hitting $15.50. The company’s stock had a trading volume of 490,907 shares, compared to its average volume of 869,960. The company has a quick ratio of 1.38, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $1.33 billion, a P/E ratio of -5.21, a P/E/G ratio of 2.26 and a beta of 1.55. Pediatrix Medical Group, Inc. has a twelve month low of $6.62 and a twelve month high of $16.41. The stock’s fifty day moving average price is $12.19 and its two-hundred day moving average price is $9.69.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the previous year, the company posted $0.29 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. Research analysts forecast that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MD shares. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Jefferies Financial Group raised their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. UBS Group raised their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and an average target price of $16.10.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently modified their holdings of MD. Algert Global LLC acquired a new stake in shares of Pediatrix Medical Group in the 3rd quarter valued at $1,315,000. Intech Investment Management LLC lifted its stake in shares of Pediatrix Medical Group by 29.6% in the 3rd quarter. Intech Investment Management LLC now owns 40,662 shares of the company’s stock valued at $471,000 after purchasing an additional 9,289 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Pediatrix Medical Group by 60.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 263,410 shares of the company’s stock valued at $3,053,000 after purchasing an additional 99,324 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after purchasing an additional 622 shares during the last quarter. Finally, Empowered Funds LLC lifted its position in Pediatrix Medical Group by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 266,838 shares of the company’s stock worth $3,093,000 after acquiring an additional 13,534 shares during the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.